# Shorter epinephrine dosing intervals and one-year survival after in-hospital pediatric cardiopulmonary resuscitation

**Authors:** Bruno Marcelo Herculano Moura, Edison Ferreira de Paiva, Ivan Peres Costa, Thomaz Bittencourt Couto, Cláudio Schvartsman, Tania Miyuki Shimoda Sakano, Amelia Gorete Reis

PMC · DOI: 10.1016/j.jped.2026.101520 · 2026-03-05

## TL;DR

This study examines how the timing of epinephrine doses affects survival and neurological outcomes in children who experience cardiac arrest in the hospital.

## Contribution

The study is one of the first to investigate the association between epinephrine dosing intervals and one-year survival in pediatric in-hospital cardiac arrest.

## Key findings

- Shorter epinephrine dosing intervals were associated with increased one-year survival in univariate analysis.
- Multivariable analysis showed that longer dosing intervals and other factors were linked to reduced survival.
- No significant association was found between epinephrine dosing intervals and neurological outcomes.

## Abstract

To evaluate the association between the interval doses of epinephrine and one-year survival and one-year neurological prognosis after pediatric in-hospital cardiac arrest (IHCA).

This observational retrospective cohort study included pediatric patients (0–18 years) who experienced IHCA and received at least two doses of epinephrine from January 2015 to December 2022. Data were collected following the Utstein style. The mean interval between epinephrine doses was categorized as 〈 3, 3–5, or > 5 min. Primary outcome was one-year survival; secondary outcomes were survival to hospital discharge and one-year neurological prognosis, assessed by the Pediatric Cerebral Performance Category.

194 patients were eligible. In the univariate adjusted analysis, patients who received epinephrine at intervals shorter than 3 min had a 2.3-fold increased chance of one-year survival (OR 2.3; 95 % CI 1.0–5.5; p = 0.042), although this association was not sustained in the multivariable regression. Longer intervals between epinephrine doses (OR: 0.71; 95 % CI 0.52–0.71; p = 0.03), continuous vasoactive drugs infusion prearrest (OR 0.1; 95 % CI 0.1–0.4; p < 0.001), longer resuscitation duration (OR 0.8; 95 % CI 0.7–0.9; p = 0.028), epinephrine doses (OR 0.68; 95 % CI 0.56–0.81; p < 0.001) were associated with reduced one-year survival. Neurological deterioration was observed in 6 (16.6 %) of the 36 patients after one year (p = 0.001). No association was found between epinephrine dosing intervals (OR 0.72; 95 % CI 0.16–3.14; p = 0.65) and neurological outcomes.

Epinephrine dosing interval was not independently associated with one-year survival after adjusted analyses. These findings underscore the complexity of pediatric resuscitation and support further multicenter prospective studies.

## Linked entities

- **Chemicals:** epinephrine (PubChem CID 838)
- **Diseases:** cardiac arrest (MONDO:0000745)

## Full-text entities

- **Diseases:** Bradycardia (MESH:D001919), ischemia (MESH:D007511), arrhythmias (MESH:D001145), CA (MESH:D006323), VF (MESH:C537182), PCPC (MESH:C538175), critically ill (MESH:D016638), IHCA (MESH:D058687), trauma (MESH:D014947), circulatory collapse (MESH:D012769), neurological disability (MESH:D009069), Neurological deterioration (MESH:D009422), ventricular tachycardia (MESH:D017180), ventricular fibrilatrion (MESH:D014693), ROSC (MESH:D005598), death (MESH:D003643), neurological damage (MESH:D020196), cardiorespiratory collapse (MESH:D001261)
- **Chemicals:** Epinephrine (MESH:D004837), vasoactive drug (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12972964/full.md

---
Source: https://tomesphere.com/paper/PMC12972964